Is Oxazepam 10mg tablets a controlled drug in the UK?

Yes, Oxazepam 10mg tablets is classified as Schedule 4 (CD Benz) under the UK Misuse of Drugs Regulations. This means there are special legal requirements for prescribing, dispensing, and storing this medicine. (Source: NHS dm+d, UK Misuse of Drugs Regulations 2001)

Do I need a prescription for Oxazepam 10mg tablets?

Oxazepam 10mg tablets is classified as a Valid as a prescribable product in the UK. However, always consult a pharmacist or doctor before use. (Source: NHS dm+d)

What are the brand names for Oxazepam 10mg tablets?

Oxazepam 10mg tablets is the generic name. It is available under brand names including: Oxazepam 10mg tablets, Oxazepam 10mg tablets, Oxazepam 10mg tablets, Oxazepam 10mg tablets, Oxazepam 10mg tablets and 7 more. (Source: NHS dm+d — Actual Medicinal Products)

Oxazepam 10mg tablets

Prescription only

Requires a prescription from a doctor or prescriber

Tablet

10mg

Oral

Oxazepam is an intermediate-acting, 3-hydroxybenzodiazepine used in the treatment of alcohol withdrawal and anxiety disorders.

Active ingredients:

Oxazepam

CD Schedule 4

Minimal controls; includes benzodiazepines and anabolic steroids

details

BNF classificationBrowse formulary

Where this medicine sits in the British National Formulary — the UK's standard prescribing reference

BNF 04.01.02

ATC classificationBrowse ATC index

International classification by the WHO, grouping medicines by the organ system they act on

ATC N05BA04

Chemical classBrowse classes

Classification based on the molecule's chemical structure and properties

Check interactions for Oxazepam

1 safety notice

Schedule 4

Legal requirements and restrictions

Benzodiazepines and similar medicines. Subject to minimal controlled drug requirements.

Legal requirements

Prescriptions valid for 28 days
No controlled drugs register required
No safe custody requirements
Record keeping requirements for imports/exports

Other medicines in this category

Diazepam, Lorazepam, Nitrazepam, Zolpidem, Zopiclone

View full UK controlled drugs list

Official documents, adverse reaction reporting, and safety monitoring

Report a side effect

Submit a Yellow Card report to the MHRA

Official medicine documents

Yellow Card

Report side effects (MHRA)

Drug safety updates

MHRA alerts for Oxazepam

Source: MHRA Products DatabaseOGL 3.0

Updated 3 months ago(16 Jan 2026)

Safety monitoring data

Yellow Card reports

MHRA

The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.

View Drug Analysis Profile

Suspected adverse reactions reported for Oxazepam

Browse all iDAP reports

Interactive Drug Analysis Profiles for all medicines

Report a side effect

Submit a Yellow Card report to the MHRA

Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.

EudraVigilance

EMA

The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.

View EudraVigilance report

Suspected adverse reactions reported for Oxazepam

About EudraVigilance

Learn about EU pharmacovigilance and safety monitoring

EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.

12 branded products available

12 productsShow details

12 products

Possibly available on the UK marketDiscontinuedAvailability per NHS dm+d

MHRA licensed products

View all licensed products for Oxazepam on the MHRA register

Oxazepam 10mg tablets

A A H Pharmaceuticals Ltd

Oxazepam 10mg tablets

Accord-UK Ltd

Oxazepam 10mg tablets

Genus Pharmaceuticals Holdings Ltd

Oxazepam 10mg tablets

Alliance Healthcare (Distribution) Ltd

Oxazepam 10mg tablets

Phoenix Healthcare Distribution Ltd

Oxazepam 10mg tablets

Almus Pharmaceuticals Ltd

Oxazepam 10mg tablets

Sigma Pharmaceuticals Plc

Oxazepam 10mg tablets

Medihealth (Northern) Ltd

Oxazepam 10mg tablets

Tillomed Laboratories Ltd

Oxazepam 10mg tablets

Kent Pharma (UK) Ltd

Discontinued

Oxazepam 10mg tablets

Waymade Healthcare Plc

Discontinued

Oxazepam 10mg tablets

DE Pharmaceuticals

Discontinued

Source: NHS dm+dOGL 3.0

Updated about 1 month ago(1 Mar 2026)

Price & daily doseShow details

£3.16indicative price

This is the NHS Drug Tariff indicative price used for reimbursement purposes. It may not reflect the price paid by patients or pharmacies.

View full Drug Tariff

Source: NHS Drug Tariff via NHSBSA. Derived from dm+d VMPP (Virtual Medicinal Product Pack) pricing data. Contains public sector information licensed under the Open Government Licence v3.0.

WHO defined daily dose (DDD)

50 mg

Not a recommended dose. The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. It is a statistical measure used for research and comparison purposes only.

Source: WHO Collaborating Centre for Drug Statistics Methodology, distributed via NHS dm+d BNF mapping files. Contains public sector information licensed under the Open Government Licence v3.0.

Therapeutically similar medicines

10 similarShow details

Diazepam 2mg/5ml oral suspension sugar free

Oral suspension

2mg/5ml

Same therapeutic group

Clobazam 20mg tablets

Tablet

20mg

Same therapeutic group

Lorazepam 250microgram tablets

Tablet

Same therapeutic group

Lorazepam 4mg/1ml solution for injection vials

Injection

4mg/1ml

Same therapeutic group

Lorazepam 2mg/1ml solution for injection cartridges

Injection

2mg/1ml

Same therapeutic group

Similarity based on WHO Anatomical Therapeutic Chemical (ATC) classification and NHS BNF section grouping. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.

NHS prescribing volume and spending trends

Show details

Loading prescribing data...

Clinical guidelines and formulary information

British National Formulary

Oxazepam

BNF

Drug monograph — bnf.nice.org.uk

Source: British National Formulary, NICE. Joint Formulary Committee. Contains public sector information licensed under the Open Government Licence v3.0.

Check stock at pharmacies and supply information

Show details

Pharmacy stock checkers

Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.

Boots

Search products

Click & collectNHS

Lloyds

Search products

DeliveryNHS

P2U

Pharmacy2U

Search products

DeliveryNHS

Supply & product information

Official product databases and supply status monitoring

Shortages info

NHS Specialist Pharmacy Service (SPS)

emc product search

Discontinuations & alternatives for Oxazepam

Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. emc (electronic medicines compendium) is operated by Datapharm Ltd. Shortage information sourced from NHS Specialist Pharmacy Service (SPS), sps.nhs.uk.

Codes for healthcare professionals and prescribing systems

Show details

These codes are used by healthcare IT systems and prescribers to identify this medicine.

NHS UK identifiers

SNOMED CT

42132611000001109

dm+d ID

42132611000001109

VTM (Virtual Therapeutic Moiety)

777016003

VMP (Virtual Medicinal Product)

42132611000001109

BNF code

04010200

International identifiers

ATC code — Anatomical Therapeutic Chemical (WHO)

N05BA04

Browse tools

dm+d Browser

NHSBSA medicines dictionary lookup

SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF codes from NHS Business Services Authority (NHSBSA). ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).

Active and completed clinical studies from ClinicalTrials.gov

Show details

Searching UK clinical trials...

Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.

Pharmacology and chemical data from DrugBank

go.drugbank.com

Key facts

Drug status

Approved

Major interactions

2 found

Half-life

8.2 hours

Mechanism

Like other benzodiazepines, oxazepam exerts its anxiolytic effects by potentiati…

Food interactions

1 warning

Human targets

3 targets

Data: DrugBank · CC BY-NC 4.0

Pharmacokinetics at a glance

Absorption

450 mg/mL

Following oral administration, peak plasma levels (C_max) averaged 450 mg/mL and occurred approximately 3 hours (T_max) after dosing.
[L13895]

Half-life

8.2 hours

The mean elimination half-life of oxazepam is 8.2 hours.
[L13895]

Protein binding

89%

Plasma protein binding is approximately 89%,[L13898] likely to albumin.
[A203354]

Metabolism

Oxazepam has a single major inactive metabolite, a glucuronide conjugate.
[L13895]…

Elimination

21%

Oxazepam is primarily eliminated in the urine as its glucuronide metabolite, with the feces containing approximately 21% of the unchanged drug.
[L13898]…

Pharmacokinetic data: DrugBank · CC BY-NC 4.0

Status:

Approved

Small molecule

About this compound

Oxazepam is an intermediate-acting, 3-hydroxybenzodiazepine used in the treatment of alcohol withdrawal and anxiety disorders. Oxazepam, like related 3-hydroxybenzodiazepine [lorazepam], is considered less susceptible to pharmacokinetic variability based on patient-specific factors (e.g. age, liver disease) - this feature is advantageous as compared to other benzodiazepines, and is likely owing in part to oxazepam's relatively simple metabolism.[A203516] It is an active metabolite of both [diazepam] and [temazepam][A39486] and undergoes very little biotransformation following absorption, making it unlikely to participate in pharmacokinetic interactions.[L13895]

Properties:

solid

Avg. mass: 286.71 Da

DrugBank indication

Oxazepam is indicated for the management of anxiety disorders and for the short-term relief of symptoms of anxiety.
[L13895]
It may also be used in the management of alcohol withdrawal symptoms.
[L13895]

Also known as(84)

(+-)-Oxazepam

(RS)-Oxazepam

Oxazepam

GABA(A) receptor subunit alpha-1

GABAAR subunit alpha-1

GABA(A) receptor subunit alpha-2

GABAAR subunit alpha-2

GABA(A) receptor subunit alpha-3

Dosage forms(19)

Tablet (Oral)

Capsule (Oral)

Tablet (Oral) — 10 mg

Tablet (Oral) — 15 mg

Tablet (Oral) — 30 mg

Tablet (Oral) — 50 MG

Pill (Oral) — 10 MG

Pill (Oral) — 25 MG

Molecular properties(19)

Drug interactions(1348)

Known interactions with other medications. Always consult a healthcare professional.

Buprenorphine

Moderate

DB00921

Oxazepam may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.

Check this interaction

Doxylamine

Moderate

DB00366

Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Oxazepam.

Check this interaction

Dronabinol

Moderate

DB00470

Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Oxazepam.

Check this interaction

Droperidol

Moderate

DB00450

Droperidol may increase the central nervous system depressant (CNS depressant) activities of Oxazepam.

Check this interaction

Hydrocodone

Moderate

DB00956

Oxazepam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.

Check this interaction

Hydroxyzine

Moderate

DB00557

Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Oxazepam.

Check this interaction

Magnesium sulfate

Moderate

DB00653

The therapeutic efficacy of Oxazepam can be increased when used in combination with Magnesium sulfate.

Check this interaction

Methotrimeprazine

Moderate

DB01403

Oxazepam may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.

Check this interaction

Metyrosine

Moderate

DB00765

Oxazepam may increase the sedative activities of Metyrosine.

Check this interaction

Minocycline

Moderate

DB01017

Minocycline may increase the central nervous system depressant (CNS depressant) activities of Oxazepam.

Check this interaction

Mirtazapine

Moderate

DB00370

Oxazepam may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.

Check this interaction

Nabilone

Moderate

DB00486

Nabilone may increase the central nervous system depressant (CNS depressant) activities of Oxazepam.

Check this interaction

Orphenadrine

Moderate

DB01173

Oxazepam may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.

Check this interaction

Paraldehyde

Moderate

DB09117

Oxazepam may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.

Check this interaction

Perampanel

Moderate

DB08883

Perampanel may increase the central nervous system depressant (CNS depressant) activities of Oxazepam.

Check this interaction

Pramipexole

Moderate

DB00413

Oxazepam may increase the sedative activities of Pramipexole.

Check this interaction

Ropinirole

Moderate

DB00268

Oxazepam may increase the sedative activities of Ropinirole.

Check this interaction

Rotigotine

Moderate

DB05271

Oxazepam may increase the sedative activities of Rotigotine.

Check this interaction

Rufinamide

Unknown severity

DB06201

The risk or severity of adverse effects can be increased when Rufinamide is combined with Oxazepam.

Check this interaction

Suvorexant

Moderate

DB09034

Oxazepam may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.

Check this interaction

Tapentadol

Moderate

DB06204

Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Oxazepam.

Check this interaction

Thalidomide

Moderate

DB01041

Oxazepam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.

Check this interaction

Zolpidem

Moderate

DB00425

Oxazepam may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.

Check this interaction

Clozapine

Unknown severity

DB00363

The risk or severity of adverse effects can be increased when Oxazepam is combined with Clozapine.

Check this interaction

Methadone

Moderate

DB00333

Oxazepam may increase the central nervous system depressant (CNS depressant) activities of Methadone.

Check this interaction

Sodium oxybate

Moderate

DB09072

Oxazepam may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.

Check this interaction

Teduglutide

Unknown severity

DB08900

The serum concentration of Oxazepam can be increased when it is combined with Teduglutide.

Check this interaction

Yohimbine

Moderate

DB01392

The therapeutic efficacy of Oxazepam can be increased when used in combination with Yohimbine.

Check this interaction

Flumazenil

Moderate

DB01205

Flumazenil may decrease the sedative activities of Oxazepam.

Check this interaction

Ethanol

Moderate

DB00898

Oxazepam may increase the central nervous system depressant (CNS depressant) activities of Ethanol.

Check this interaction

Azelastine

Moderate

DB00972

Oxazepam may increase the central nervous system depressant (CNS depressant) activities of Azelastine.

Check this interaction

Brimonidine

Moderate

DB00484

Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Oxazepam.

Check this interaction

Zimelidine

Unknown severity

DB04832

The risk or severity of adverse effects can be increased when Oxazepam is combined with Zimelidine.

Check this interaction

Dapoxetine

Unknown severity

DB04884

The risk or severity of adverse effects can be increased when Oxazepam is combined with Dapoxetine.

Check this interaction

Seproxetine

Unknown severity

DB06731

The risk or severity of adverse effects can be increased when Oxazepam is combined with Seproxetine.

Check this interaction

Fluvoxamine

Unknown severity

DB00176

The risk or severity of adverse effects can be increased when Oxazepam is combined with Fluvoxamine.

Check this interaction

Citalopram

Unknown severity

DB00215

The risk or severity of adverse effects can be increased when Oxazepam is combined with Citalopram.

Check this interaction

Duloxetine

Unknown severity

DB00476

The risk or severity of adverse effects can be increased when Oxazepam is combined with Duloxetine.

Check this interaction

Trazodone

Unknown severity

DB00656

The risk or severity of adverse effects can be increased when Oxazepam is combined with Trazodone.

Check this interaction

Paroxetine

Unknown severity

DB00715

The risk or severity of adverse effects can be increased when Oxazepam is combined with Paroxetine.

Check this interaction

Sertraline

Unknown severity

DB01104

The risk or severity of adverse effects can be increased when Oxazepam is combined with Sertraline.

Check this interaction

Sibutramine

Unknown severity

DB01105

The risk or severity of adverse effects can be increased when Oxazepam is combined with Sibutramine.

Check this interaction

Nefazodone

Unknown severity

DB01149

The risk or severity of adverse effects can be increased when Oxazepam is combined with Nefazodone.

Check this interaction

Escitalopram

Unknown severity

DB01175

The risk or severity of adverse effects can be increased when Oxazepam is combined with Escitalopram.

Check this interaction

Milnacipran

Unknown severity

DB04896

The risk or severity of adverse effects can be increased when Oxazepam is combined with Milnacipran.

Check this interaction

Desvenlafaxine

Unknown severity

DB06700

The risk or severity of adverse effects can be increased when Oxazepam is combined with Desvenlafaxine.

Check this interaction

Levomilnacipran

Unknown severity

DB08918

The risk or severity of adverse effects can be increased when Oxazepam is combined with Levomilnacipran.

Check this interaction

Indalpine

Unknown severity

DB08953

The risk or severity of adverse effects can be increased when Oxazepam is combined with Indalpine.

Check this interaction

Ritanserin

Unknown severity

DB12693

The risk or severity of adverse effects can be increased when Oxazepam is combined with Ritanserin.

Check this interaction

Alaproclate

Unknown severity

DB13233

The risk or severity of adverse effects can be increased when Oxazepam is combined with Alaproclate.

Check this interaction

Showing 50 of 1348 interactions

Food & lifestyle interactions

Avoid Alcohol

Avoid alcohol. Co-administration with alcohol may potentiate the CNS effects of oxazepam.

Toxicity & overdose

The oral LD₅₀ in rats and mice is >8000 mg/kg and 1540 mg/kg, respectively.
[L13904]

Symptoms of oxazepam overdose are likely to be consistent with its adverse effect profile and range from mild to severe, sometimes fatal, CNS depression.
[L13895]
Treatment should include gastric decontamination, via lavage or induced vomiting, followed by symptomatic and supportive measures. The benzodiazepine antagonist [flumazenil] may be used in hospitalized patients as an adjunct to non-pharmacological management, but may increase the risk of seizure in long-term benzodiazepine users and in cyclic antidepressant overdose.
[L13895]

How it works

Mechanism of action

Like other benzodiazepines, oxazepam exerts its anxiolytic effects by potentiating the effect of gamma-aminobutyric acid (GABA) on GABA(A) receptors, the main inhibitory neurotransmitter receptors in the mammalian brain.[A198957] GABA(A) receptors are a component of GABA-gated ionotropic chloride channels that produce inhibitory postsynaptic potentials - following activation by GABA, the channel undergoes a conformational change that allows the passage of chloride ions through the channel. The inhibitory potentials produced by GABA neurotransmission play an integral role in the suppression and control of epileptiform nerve firing such as that seen in epilepsy, which makes the GABA system a desirable target in the treatment of epilepsy.

Benzodiazepines are positive allosteric modulators of GABA(A) function. They bind to the interface between alpha (α) and gamma (γ) subunits on the receptor, commonly referred to as the benzodiazepine binding site, and modulate the receptor such that its inhibitory response to GABA binding is dramatically increased.[A198957]

Pharmacodynamics

Benzodiazepines, including oxazepam, exert their sedative and anxiolytic effects by potentiating the effects of endogenous GABA, the primary inhibitory neurotransmitter in the CNS.[A34430] Compared to other benzodiazepines, it has relatively low potency and a moderate duration of action.[A34430] Oxazepam should be administered with caution to patients for whom a drop in blood pressure may lead to cardiac complications as, in rare cases, it may cause hypotension.[L13895]

Pharmacokinetics

How the body processes this drug — absorption, distribution, metabolism, and elimination

Absorption

Following oral administration, peak plasma levels (C_max) averaged 450 mg/mL and occurred approximately 3 hours (T_max) after dosing.
[L13895]

Half-life

The mean elimination half-life of oxazepam is 8.2 hours.
[L13895]

Protein binding

Plasma protein binding is approximately 89%,[L13898] likely to albumin.
[A203354]

Metabolism

Oxazepam has a single major inactive metabolite, a glucuronide conjugate.
[L13895]
The glucuronidation of the S-isomer is catalyzed by UGT2B15. The glucuronidation of the R-isomer is catalyzed by UGT2B7 and UGT1A9.
[A18016]

Route of elimination

Oxazepam is primarily eliminated in the urine as its glucuronide metabolite, with the feces containing approximately 21% of the unchanged drug.
[L13898]
The majority of an orally ingested dose of oxazepam is excreted within 48 hours.
[L13898]

Drug targets(3)

Proteins and enzymes this drug interacts with in the body

Gamma-aminobutyric acid receptor subunit theta

BE0004797

GABRQ

positive allosteric modulator

Specific functionGABA-A receptor activity

Cellular location

Postsynaptic cell membrane

General function & pharmacology

Theta subunit of the heteropentameric ligand-gated chloride channel gated by gamma-aminobutyric acid (GABA), a major inhibitory neurotransmitter in the brain .
PMID:10449790 PMID:16412217
GABA-gated chloride channels, also named GABA(A) receptors (GABAAR), consist of five subunits arranged around a central pore and contain GABA active binding site(s) located at the alpha and beta subunit interfaces (By similarity). When activated by GABA, GABAARs selectively allow the flow of chloride anions across the cell membrane down their electrochemical gradient PMID:10449790 PMID:16412217

Gamma-aminobutyric acid receptor subunit gamma-3

BE0008668

GABRG3

ligand

Specific functionGABA-A receptor activity

Cellular location

Postsynaptic cell membrane

General function & pharmacology

Gamma subunit of the heteropentameric ligand-gated chloride channel gated by gamma-aminobutyric acid (GABA), a major inhibitory neurotransmitter in the brain (By similarity). GABA-gated chloride channels, also named GABA(A) receptors (GABAAR), consist of five subunits arranged around a central pore and contain GABA active binding site(s) located at the alpha and beta subunit interface(s) (By similarity). When activated by GABA, GABAARs selectively allow the flow of chloride across the cell membrane down their electrochemical gradient (By similarity)

Translocator protein

BE0000736

TSPO

agonist

Specific functionandrogen binding

Cellular location

Mitochondrion membrane

General function & pharmacology

Can bind protoporphyrin IX and may play a role in the transport of porphyrins and heme (By similarity). Promotes the transport of cholesterol across mitochondrial membranes and may play a role in lipid metabolism PMID:24814875, but its precise physiological role is controversial. It is apparently not required for steroid hormone biosynthesis.

Was initially identified as peripheral-type benzodiazepine receptor; can also bind isoquinoline carboxamides PMID:1847678

Metabolizing enzymes(3)

Enzymes involved in drug metabolism — important for understanding drug interactions

Enzyme activity key

substrate

inhibitor

inducer

UGT2B15UDP-glucuronosyltransferase 2B15

substrate

UGT2B7UDP-glucuronosyltransferase 2B7

substrate

UGT1A9UDP-glucuronosyltransferase 1A9

substrate

Carriers(1)

Proteins that carry this drug through the body

Albumin

BE0000530

ALB

binder

Specific functionantioxidant activity

Cellular location

Secreted

General function & pharmacology

Binds water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs (Probable). Its main function is the regulation of the colloidal osmotic pressure of blood (Probable). Major zinc transporter in plasma, typically binds about 80% of all plasma zinc .
PMID:19021548
Major calcium and magnesium transporter in plasma, binds approximately 45% of circulating calcium and magnesium in plasma (By similarity).

Potentially has more than two calcium-binding sites and might additionally bind calcium in a non-specific manner (By similarity). The shared binding site between zinc and calcium at residue Asp-273 suggests a crosstalk between zinc and calcium transport in the blood (By similarity). The rank order of affinity is zinc > calcium > magnesium (By similarity).

Binds to the bacterial siderophore enterobactin and inhibits enterobactin-mediated iron uptake of E.coli from ferric transferrin, and may thereby limit the utilization of iron and growth of enteric bacteria such as E.coli .
PMID:6234017
Does not prevent iron uptake by the bacterial siderophore aerobactin PMID:6234017

Scientific references(13)

Peppers M.P.

Benzodiazepines for Alcohol Withdrawal in the Elderly and in Patients With Liver Disease.

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

199616(1):49-58. doi: 10.1002/j.1875-9114.1996.tb02915.x

PMID: 8700792 DOI: 10.1002/j.1875-9114.1996.tb02915.x

Skerritt J.H., Johnston G.A.

Enhancement of GABA binding by benzodiazepines and related anxiolytics.

European Journal of Pharmacology

198389(3-4):193-198. doi: 10.1016/0014-2999(83)90494-6

PMID: 6135616 DOI: 10.1016/0014-2999(83)90494-6

Oelschlager H.

Chemical models of vitrinite reflectance evolution.

Geologische Rundschau

198978(1):349-359. doi: 10.1007/bf01988369

PMID: 2570451 DOI: 10.1007/bf01988369

Christensen P., Lolk A., Gram L.F., Kragh-Sorensen P.

Benzodiazepine-induced sedation and cortisol suppression.

Psychopharmacology

1992106(4):511-516. doi: 10.1007/bf02244823

PMID: 1349754 DOI: 10.1007/bf02244823

Olive G., Dreux C.

Radiological Case of the Month.

Archives of Pediatrics & Adolescent Medicine

1977131(1):89. doi: 10.1001/archpedi.1977.02120140091015

PMID: 851373 DOI: 10.1001/archpedi.1977.02120140091015

Altamura A.C., Moliterno D., Paletta S., Maffini M., Mauri M.C., Bareggi S.

Understanding the pharmacokinetics of anxiolytic drugs.

Expert Opinion Drug Metabolism Toxicology

2013 Apr9(4):423-40. doi: 10.1517/17425255.2013.759209. Epub 2013 Jan 21

PMID: 23330992 DOI: 10.1517/17425255.2013.759209

Chin P.K., Jensen B.P., Larsen H.S., Begg E.J.

Adult age and ex vivo protein binding of lorazepam, oxazepam and temazepam in healthy subjects.

British Journal of Clinical Pharmacology

2011 Dec72(6):985-9. doi: 10.1111/j.1365-2125.2011.04036.x

PMID: 21671987 DOI: 10.1111/j.1365-2125.2011.04036.x

Sigel E., Steinmann M.E.

Structure, function, and modulation of GABA(A) receptors.

Journal of Biological Chemistry

2012 Nov 23287(48):40224-31. doi: 10.1074/jbc.R112.386664. Epub 2012 Oct 4

PMID: 23038269 DOI: 10.1074/jbc.R112.386664

Zhu S., Noviello C.M., Teng J., Walsh RM Jr, Kim J.J., Hibbs R.E.

Structure of a human synaptic GABAA receptor.

Nature

2018 Jul559(7712):67-72. doi: 10.1038/s41586-018-0255-3. Epub 2018 Jun 27

PMID: 29950725 DOI: 10.1038/s41586-018-0255-3

Griffin CE 3rd, Kaye A.M., Bueno F.R., Kaye A.D.

214 Effects of cocaine on the central nervous system.

Biochemical Pharmacology

19618(1):67. doi: 10.1016/0006-2952(61)90393-8

PMID: 23789008 DOI: 10.1016/0006-2952(61)90393-8

Shader R.I., Greenblatt D.J.

The use of benzodiazepines in clinical practice.

British Journal of Clinical Pharmacology

198111 Suppl 1:5S-9S. doi: 10.1111/j.1365-2125.1981.tb01832.x

PMID: 6133535 DOI: 10.1111/j.1365-2125.1981.tb01832.x

Calcaterra N.E., Barrow J.C.

Classics in chemical neuroscience: diazepam (valium).

ACS Chemistry Neurosci

2014 Apr 165(4):253-60. doi: 10.1021/cn5000056. Epub 2014 Feb 27

PMID: 24552479 DOI: 10.1021/cn5000056

Court M.H., Duan S.X., Guillemette C., Journault K., Krishnaswamy S., Von Moltke L.L., Greenblatt D.J.

Stereoselective Conjugation of Oxazepam by Human UDP-Glucuronosyltransferases (UGTs): S-Oxazepam Is Glucuronidated by UGT2B15, While R-Oxazepam Is Glucuronidated by UGT2B7 and UGT1A9.

Drug Metabolism and Disposition

200230(11):1257-1265. doi: 10.1124/dmd.30.11.1257

PMID: 12386133 DOI: 10.1124/dmd.30.11.1257

ATC classification(1 code)

ATC N05BA04

Affected organisms(1)

Humans and other mammals

International brands(24)

Experimental properties(2)

External resources(3)

RxList PDRhealth Drugs.com

Commercial products(64)

Chemical identifiers

CAS, UNII, InChI Key and database cross-references

Show

Linked compound data from DrugBank Open Data (CC BY-NC 4.0)

Oxazepam

DB00842

CAS number

604-75-1

UNII (FDA)

6GOW6DWN2A

InChI Key (molecular fingerprint)

ADIMAYPTOBDMTL-UHFFFAOYSA-N

Additional database identifiers

Drugs Product Database (DPD)

9956

ChEBI

7823

PubChem Compound

4616

PubChem Substance

46506031

KEGG Compound

C07359

KEGG Drug

D00464

ChemSpider

4455

BindingDB

85031

PharmGKB

PA450731

Therapeutic Targets Database

DAP000243

Wikipedia

Oxazepam

ChEMBL

CHEMBL568

RxCUI

7781

HUGO Gene Nomenclature Committee (HGNC)

HGNC:4075

GenAtlas

GABRA1

GeneCards

GABRA1

GenBank Gene Database

X13584

GenBank Protein Database

31631

IUPHAR

404

Guide to Pharmacology

404

UniProtKB

P14867

UniProt Accession

GBRA1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:4076

GenAtlas

GABRA2

GeneCards

GABRA2

GenBank Gene Database

S62907

GenBank Protein Database

386422

IUPHAR

405

Guide to Pharmacology

405

UniProtKB

P47869

UniProt Accession

GBRA2_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:4077

GenAtlas

GABRA3

GeneCards

GABRA3

GenBank Gene Database

S62908

GenBank Protein Database

386424

IUPHAR

406

Guide to Pharmacology

406

UniProtKB

P34903

UniProt Accession

GBRA3_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:4078

GenAtlas

GABRA4

GeneCards

GABRA4

GenBank Gene Database

U30461

GenBank Protein Database

905393

IUPHAR

407

Guide to Pharmacology

407

UniProtKB

P48169

UniProt Accession

GBRA4_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:4079

GenAtlas

GABRA5

GeneCards

GABRA5

GenBank Gene Database

L08485

GenBank Protein Database

182916

IUPHAR

408

Guide to Pharmacology

408

UniProtKB

P31644

UniProt Accession

GBRA5_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:4080

GenAtlas

GABRA6

GeneCards

GABRA6

GenBank Gene Database

S81944

GenBank Protein Database

1470364

IUPHAR

409

Guide to Pharmacology

409

UniProtKB

Q16445

UniProt Accession

GBRA6_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:4081

GenAtlas

GABRB1

GeneCards

GABRB1

GenBank Gene Database

X14767

GenBank Protein Database

31635

IUPHAR

410

UniProtKB

P18505

UniProt Accession

GBRB1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:4082

GenAtlas

GABRB2

GeneCards

GABRB2

GenBank Gene Database

S67368

GenBank Protein Database

455946

IUPHAR

411

UniProtKB

P47870

UniProt Accession

GBRB2_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:4083

GenAtlas

GABRB3

GeneCards

GABRB3

GenBank Gene Database

M82919

GenBank Protein Database

182925

IUPHAR

412

Guide to Pharmacology

412

UniProtKB

P28472

UniProt Accession

GBRB3_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:4084

GeneCards

GABRD

GenBank Gene Database

AF016917

GenBank Protein Database

2388693

UniProtKB

O14764

UniProt Accession

GBRD_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:4085

GeneCards

GABRE

GenBank Gene Database

U66661

GenBank Protein Database

1857126

UniProtKB

P78334

UniProt Accession

GBRE_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:4086

GeneCards

GABRG1

GenBank Gene Database

AK122845

GenBank Protein Database

193783776

UniProtKB

Q8N1C3

UniProt Accession

GBRG1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:4087

GeneCards

GABRG2

GenBank Gene Database

X15376

GenBank Protein Database

31637

UniProtKB

P18507

UniProt Accession

GBRG2_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:4088

GeneCards

GABRG3

GenBank Gene Database

S82769

GenBank Protein Database

1754749

UniProtKB

Q99928

UniProt Accession

GBRG3_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:4089

GeneCards

GABRP

GenBank Gene Database

U95367

GenBank Protein Database

2197001

UniProtKB

O00591

UniProt Accession

GBRP_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:14454

GeneCards

GABRQ

GenBank Gene Database

AF189259

GenBank Protein Database

7861736

UniProtKB

Q9UN88

UniProt Accession

GBRT_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:4075

GenAtlas

GABRA1

GeneCards

GABRA1

GenBank Gene Database

X13584

GenBank Protein Database

31631

IUPHAR

404

Guide to Pharmacology

404

UniProtKB

P14867

UniProt Accession

GBRA1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:4076

GenAtlas

GABRA2

GeneCards

GABRA2

GenBank Gene Database

S62907

GenBank Protein Database

386422

IUPHAR

405

Guide to Pharmacology

405

UniProtKB

P47869

UniProt Accession

GBRA2_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:4077

GenAtlas

GABRA3

GeneCards

GABRA3

GenBank Gene Database

S62908

GenBank Protein Database

386424

IUPHAR

406

Guide to Pharmacology

406

UniProtKB

P34903

UniProt Accession

GBRA3_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:4079

GenAtlas

GABRA5

GeneCards

GABRA5

GenBank Gene Database

L08485

GenBank Protein Database

182916

IUPHAR

408

Guide to Pharmacology

408

UniProtKB

P31644

UniProt Accession

GBRA5_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:4086

GeneCards

GABRG1

GenBank Gene Database

AK122845

GenBank Protein Database

193783776

UniProtKB

Q8N1C3

UniProt Accession

GBRG1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:4087

GeneCards

GABRG2

GenBank Gene Database

X15376

GenBank Protein Database

31637

UniProtKB

P18507

UniProt Accession

GBRG2_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:4088

GeneCards

GABRG3

GenBank Gene Database

S82769

GenBank Protein Database

1754749

UniProtKB

Q99928

UniProt Accession

GBRG3_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1158

GenAtlas

TSPO

GeneCards

TSPO

GenBank Gene Database

M36035

GenBank Protein Database

306883

Guide to Pharmacology

2879

UniProtKB

P30536

UniProt Accession

TSPO_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:12546

GeneCards

UGT2B15

UniProtKB

P54855

UniProt Accession

UDB15_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:12554

GeneCards

UGT2B7

GenBank Gene Database

J05428

GenBank Protein Database

340080

UniProtKB

P16662

UniProt Accession

UD2B7_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:12541

GeneCards

UGT1A9

GenBank Gene Database

S55985

GenBank Protein Database

7690346

UniProtKB

O60656

UniProt Accession

UD19_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:399

GenAtlas

ALB

GeneCards

ALB

GenBank Gene Database

V00494

GenBank Protein Database

28590

UniProtKB

P02768

UniProt Accession

ALBU_HUMAN

International reference pricing

7 formulations

Reference pricing from DrugBank. Prices are indicative and may not reflect current UK costs.

From $0.04/tablet

To $1.20/capsule

Apo-Oxazepam 10 mg Tablet

$0.04/tablet

Apo-Oxazepam 15 mg Tablet

$0.07/tablet

Apo-Oxazepam 30 mg Tablet

$0.09/tablet

Oxazepam 10 mg capsule

$0.60/capsule

Oxazepam 15 mg capsule

$0.73/capsule

Source: DrugBank. Used under CC BY-NC 4.0 academic licence for non-commercial purposes.

DrugBank citations

If you use DrugBank data in your research, please cite the following publications:

Knox C., Wilson M., Klinger C.M., et al

DrugBank 6.

0: the DrugBank Knowledgebase for 2024

Nucleic Acids Res. 2024 Jan 552(D1):D1265-D1275

PMID: 37953279

Wishart D.S., Feunang Y.D., Guo A.C., et al

DrugBank 5.

0: a major update to the DrugBank database for 2018

Nucleic Acids Res. 2017 Nov 846(D1):D1074-D1082

PMID: 29126136

Show earlier publications

Law V., Knox C., Djoumbou Y., et al

DrugBank 4.

0: shedding new light on drug metabolism

Nucleic Acids Res. 2014 Jan 142(1):D1091-7

PMID: 24203711

Knox C., Law V., Jewison T., et al

DrugBank 3.

0: a comprehensive resource for 'omics' research on drugs

Nucleic Acids Res. 2011 Jan39(Database issue):D1035-41

PMID: 21059682

Wishart D.S., Knox C., Guo A.C., et al

DrugBank: a knowledgebase for drugs, drug actions and drug targets.

Nucleic Acids Research

2008 Jan36(Database issue):D901-6

PMID: 18048412

Wishart D.S., Knox C., Guo A.C., et al

DrugBank: a comprehensive resource for in silico drug discovery and exploration.

Nucleic Acids Research

2006 Jan 134(Database issue):D668-72

PMID: 16381955

Source: go.drugbank.comCC BY-NC 4.0

Updated 27 days ago(8 Mar 2026)

Back to medicines

Oxazepam 10mg tablets

Legal requirements

Other medicines in this category

Official medicine documents

Safety monitoring data

Yellow Card reports

EudraVigilance

WHO defined daily dose (DDD)

British National Formulary

Pharmacy stock checkers

Supply & product information

NHS UK identifiers

International identifiers

Browse tools

Key facts

Pharmacokinetics at a glance

Absorption

Half-life

Protein binding

Metabolism

Elimination

Clinical essentials

Pharmacology

Deep science
7

Chemical identifiers

Oxazepam

Additional database identifiers

International reference pricing

DrugBank citations

Oxazepam 10mg tablets

Controlled drug information

Legal requirements

Other medicines in this category

Safety & regulatory

Official medicine documents

Safety monitoring data

Yellow Card reports

EudraVigilance

Brand versions and licensed products

NHS reimbursement price

WHO defined daily dose (DDD)

Medicines like this

Prescribing statistics

Guidance (NICE / BNF)

British National Formulary

Availability, stocks & shortages

Pharmacy stock checkers

Supply & product information

Professional identifiers

NHS UK identifiers

International identifiers

Browse tools

Clinical trials

DrugBank data

Key facts

Pharmacokinetics at a glance

Absorption

Half-life

Protein binding

Metabolism

Elimination

Clinical essentials

Pharmacology

Deep science7

Chemical identifiers

Oxazepam

Additional database identifiers

International reference pricing

DrugBank citations

Deep science
7